San Francisco, California, United States Alta Partners appeared to be the VC, which was created in 1996. The leading representative office of defined VC is situated in the San Francisco. The venture was found in North America in United States.
The increased amount of exits for fund were in 2014. Considering the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. When the investment is from Alta Partners the average startup value is 10-50 millions dollars. This Alta Partners works on 1 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. The fund is generally included in 7-12 deals every year.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Alta Partners, startups are often financed by Venrock, SV Health Investors, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are RiverVest, OrbiMed, Bay City Capital. In the next rounds fund is usually obtained by New Enterprise Associates, Venrock, HBM Healthcare Investments AG.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Kite Pharma, Intarcia Therapeutics, ZS Pharma The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Pharmaceutical, Biotechnology. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The current fund was established by Garrett Gruener, Guy P. Nohra, Jean Deleage. We also calculated 8 valuable employees in our database.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
BetterVet | $40M | 16 Nov 2022 | Boston, Massachusetts, United States | ||
Novome Biotechnologies | $43M | 13 Sep 2022 | South San Francisco, California, United States | ||
Everside Health | $164M | 25 Jul 2022 | Denver, Colorado, United States | ||
DEM BioPharma | $70M | 23 Jun 2022 | Cambridge, Massachusetts, United States | ||
Kelonia Therapeutics | $50M | 28 Apr 2022 | Boston, Massachusetts, United States | ||
Free Market Health | $13M | 19 Apr 2022 | Pittsburgh, Pennsylvania, United States | ||
Be Biopharma | $130M | 14 Apr 2022 | Cambridge, Massachusetts, United States | ||
ImmuneID | $50M | 23 Jun 2021 | Boston, Massachusetts, United States | ||
Transcarent | $58M | 10 Jun 2021 | San Francisco, California, United States |
– ImmuneID, Inc. has raised $50m in Series A financing.
– The round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management.
– All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.
– Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.
– Transcarent, a new and different consumer-directed health and care experience for employees of self-insured employers and their families, announced a $58m Series B investment led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, and Threshold Ventures along with existing investors Alta Partners and Jove Equity Partners.
– This round brings Transcarent’s total funding to $98m and will allow the company to respond to the demand for rapid expansion of its innovative risk-based offering for self-insured employers.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
BetterVet | $40M | 16 Nov 2022 | Boston, Massachusetts, United States | ||
Novome Biotechnologies | $43M | 13 Sep 2022 | South San Francisco, California, United States | ||
Everside Health | $164M | 25 Jul 2022 | Denver, Colorado, United States | ||
DEM BioPharma | $70M | 23 Jun 2022 | Cambridge, Massachusetts, United States | ||
Kelonia Therapeutics | $50M | 28 Apr 2022 | Boston, Massachusetts, United States | ||
Free Market Health | $13M | 19 Apr 2022 | Pittsburgh, Pennsylvania, United States | ||
Be Biopharma | $130M | 14 Apr 2022 | Cambridge, Massachusetts, United States | ||
ImmuneID | $50M | 23 Jun 2021 | Boston, Massachusetts, United States | ||
Transcarent | $58M | 10 Jun 2021 | San Francisco, California, United States |
Get matched with relevant funds
